Mental and Behavioral Health

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

See what's trending in pharmacy with a preview the Drug Topics April issue.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

The drug was previously approved in 2009 to treat schizophrenia.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.

In a conversation at this year’s American Pharmacists Association Annual Meeting & Exposition, Sa’ed Al-Olimat outlined the potential of psychedelic therapeutics in treating mental health disorders.

Four posters presented at this year’s American Pharmacists Association Annual Meeting & Exposition assessed the potential impact of pharmacist interventions on improving mental health outcomes.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Stimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.

See what's trending in pharmacy with a preview the Drug Topics March issue.

Researchers studied the effect of wildfires on mental health in California from 2011 to 2018.

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

The increasing use of antidepressants observed before and after the public health crisis suggests a concerning mental health trend, especially among females.

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.

Study results suggesting that long-term cumulative use of attention-deficit/hyperactivity disorder (ADHD) medication increases the risk of CVD could prompt potential adjustments in treatment approaches for ADHD.

Mental health challenges in the United States were exacerbated by the COVID-19 pandemic, and pharmacists are poised to help pick up the pieces.

Even during times of peak transmission, individuals preferred in-person screening over video or telephone screening for depression.

The NDA submitted by Lykos Therapeutics was assigned a Prescription Drug User Fee Act date of August 11, 2024.

A new study found that 52% of participants with treatment-refractory unipolar or bipolar depression achieved remission after 3 ketamine infusions.

After facing challenges, Biogen is discontinuing development and sales of aducanumab (Aduhelm) and focusing on lecanemab (Leqembi).

Compared to only 10% of primary and subspecialty visits, 34.5% of mental health visits took place via video in August 2023.